Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol
In this study, we made a comparative efficacy and safety assessment of two different fixed combinations of drugs, viz., tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxi...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2019-05, Vol.9 (1), p.7491, Article 7491 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 7491 |
| container_title | Scientific reports |
| container_volume | 9 |
| creator | Fuwa, Masahiro Shimazaki, Atsushi Mieda, Masafumi Yamashita, Naoko Akaishi, Takahiro Taniguchi, Takazumi Kato, Masatomo |
| description | In this study, we made a comparative efficacy and safety assessment of two different fixed combinations of drugs, viz., tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more effective in lowering IOP for a longer duration compared to LAT/CAR. We found that the difference in the intensity of IOP-lowering effect was because of the differences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafluprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic effects compared to LAT/CAR on the human corneal epithelial cells. Our findings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering effect in monkeys and toxicity on ocular surface. |
| doi_str_mv | 10.1038/s41598-019-44028-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6522485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2226432396</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-d264a16c1dce9a8bc9b0d1aab3027acceba743a1035f9e48f1c98292d29873aa3</originalsourceid><addsrcrecordid>eNp9UctKAzEUDaKoqD_gQgZcj01uMp3JRpBSH1Bwo0sJdzKJjkwnNUnF_r2xo7VuzCYh53HP5RByyugFo7waBcEKWeWUyVwIClUOO-QQqChy4AC7W-8DchLCK02nACmY3CcHnFFZlpIekqepta1Gvcqwb7KA1sRV5mwWX0xm2w_TZNrN67bH2Lo-rBG03XLhXYij2M5d57q1tMOIvRv-NfpovpBjsmexC-bk-z4ij9fTh8ltPru_uZtczXJdQBnzBsYC2VizRhuJVa1lTRuGWHMKJWptaiwFx7R3YaURlWVaViChAVmVHJEfkcvBd7Gs5ya59NFjpxa-naNfKYet-ov07Yt6du9qXACIqkgG598G3r0tTYjq1S19nzIrgJSOA5fjxIKBpdOawRu7mcCo-mpFDa2o1Ipat6Igic62s20kPx0kAh8IIUH9s_G_s_-x_QSE9Jqy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2226432396</pqid></control><display><type>article</type><title>Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol</title><source>Nature Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature OA Free Journals</source><creator>Fuwa, Masahiro ; Shimazaki, Atsushi ; Mieda, Masafumi ; Yamashita, Naoko ; Akaishi, Takahiro ; Taniguchi, Takazumi ; Kato, Masatomo</creator><creatorcontrib>Fuwa, Masahiro ; Shimazaki, Atsushi ; Mieda, Masafumi ; Yamashita, Naoko ; Akaishi, Takahiro ; Taniguchi, Takazumi ; Kato, Masatomo</creatorcontrib><description>In this study, we made a comparative efficacy and safety assessment of two different fixed combinations of drugs, viz., tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more effective in lowering IOP for a longer duration compared to LAT/CAR. We found that the difference in the intensity of IOP-lowering effect was because of the differences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafluprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic effects compared to LAT/CAR on the human corneal epithelial cells. Our findings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering effect in monkeys and toxicity on ocular surface.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-019-44028-2</identifier><identifier>PMID: 31097790</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject><![CDATA[631/154/436/2388 ; 692/308/2778 ; 692/699/3161/3169/3170 ; Animals ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - adverse effects ; Antihypertensive Agents - pharmacology ; Carteolol - administration & dosage ; Carteolol - adverse effects ; Carteolol - pharmacology ; Cell Line ; Compliance ; Cornea ; Cytotoxicity ; Drug Combinations ; Drug dosages ; Epithelial cells ; Epithelium, Corneal - drug effects ; Glaucoma ; Humanities and Social Sciences ; Humans ; Intraocular Pressure - drug effects ; Latanoprost - administration & dosage ; Latanoprost - adverse effects ; Latanoprost - pharmacology ; Macaca fascicularis ; Male ; multidisciplinary ; Pharmaceuticals ; Prostaglandins F - administration & dosage ; Prostaglandins F - adverse effects ; Prostaglandins F - pharmacology ; R&D ; Research & development ; Science ; Science (multidisciplinary) ; Timolol ; Timolol - administration & dosage ; Timolol - adverse effects ; Timolol - pharmacology]]></subject><ispartof>Scientific reports, 2019-05, Vol.9 (1), p.7491, Article 7491</ispartof><rights>The Author(s) 2019</rights><rights>The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-d264a16c1dce9a8bc9b0d1aab3027acceba743a1035f9e48f1c98292d29873aa3</citedby><cites>FETCH-LOGICAL-c527t-d264a16c1dce9a8bc9b0d1aab3027acceba743a1035f9e48f1c98292d29873aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522485/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522485/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31097790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fuwa, Masahiro</creatorcontrib><creatorcontrib>Shimazaki, Atsushi</creatorcontrib><creatorcontrib>Mieda, Masafumi</creatorcontrib><creatorcontrib>Yamashita, Naoko</creatorcontrib><creatorcontrib>Akaishi, Takahiro</creatorcontrib><creatorcontrib>Taniguchi, Takazumi</creatorcontrib><creatorcontrib>Kato, Masatomo</creatorcontrib><title>Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>In this study, we made a comparative efficacy and safety assessment of two different fixed combinations of drugs, viz., tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more effective in lowering IOP for a longer duration compared to LAT/CAR. We found that the difference in the intensity of IOP-lowering effect was because of the differences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafluprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic effects compared to LAT/CAR on the human corneal epithelial cells. Our findings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering effect in monkeys and toxicity on ocular surface.</description><subject>631/154/436/2388</subject><subject>692/308/2778</subject><subject>692/699/3161/3169/3170</subject><subject>Animals</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Carteolol - administration & dosage</subject><subject>Carteolol - adverse effects</subject><subject>Carteolol - pharmacology</subject><subject>Cell Line</subject><subject>Compliance</subject><subject>Cornea</subject><subject>Cytotoxicity</subject><subject>Drug Combinations</subject><subject>Drug dosages</subject><subject>Epithelial cells</subject><subject>Epithelium, Corneal - drug effects</subject><subject>Glaucoma</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Intraocular Pressure - drug effects</subject><subject>Latanoprost - administration & dosage</subject><subject>Latanoprost - adverse effects</subject><subject>Latanoprost - pharmacology</subject><subject>Macaca fascicularis</subject><subject>Male</subject><subject>multidisciplinary</subject><subject>Pharmaceuticals</subject><subject>Prostaglandins F - administration & dosage</subject><subject>Prostaglandins F - adverse effects</subject><subject>Prostaglandins F - pharmacology</subject><subject>R&D</subject><subject>Research & development</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Timolol</subject><subject>Timolol - administration & dosage</subject><subject>Timolol - adverse effects</subject><subject>Timolol - pharmacology</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9UctKAzEUDaKoqD_gQgZcj01uMp3JRpBSH1Bwo0sJdzKJjkwnNUnF_r2xo7VuzCYh53HP5RByyugFo7waBcEKWeWUyVwIClUOO-QQqChy4AC7W-8DchLCK02nACmY3CcHnFFZlpIekqepta1Gvcqwb7KA1sRV5mwWX0xm2w_TZNrN67bH2Lo-rBG03XLhXYij2M5d57q1tMOIvRv-NfpovpBjsmexC-bk-z4ij9fTh8ltPru_uZtczXJdQBnzBsYC2VizRhuJVa1lTRuGWHMKJWptaiwFx7R3YaURlWVaViChAVmVHJEfkcvBd7Gs5ya59NFjpxa-naNfKYet-ov07Yt6du9qXACIqkgG598G3r0tTYjq1S19nzIrgJSOA5fjxIKBpdOawRu7mcCo-mpFDa2o1Ipat6Igic62s20kPx0kAh8IIUH9s_G_s_-x_QSE9Jqy</recordid><startdate>20190516</startdate><enddate>20190516</enddate><creator>Fuwa, Masahiro</creator><creator>Shimazaki, Atsushi</creator><creator>Mieda, Masafumi</creator><creator>Yamashita, Naoko</creator><creator>Akaishi, Takahiro</creator><creator>Taniguchi, Takazumi</creator><creator>Kato, Masatomo</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20190516</creationdate><title>Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol</title><author>Fuwa, Masahiro ; Shimazaki, Atsushi ; Mieda, Masafumi ; Yamashita, Naoko ; Akaishi, Takahiro ; Taniguchi, Takazumi ; Kato, Masatomo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-d264a16c1dce9a8bc9b0d1aab3027acceba743a1035f9e48f1c98292d29873aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>631/154/436/2388</topic><topic>692/308/2778</topic><topic>692/699/3161/3169/3170</topic><topic>Animals</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Carteolol - administration & dosage</topic><topic>Carteolol - adverse effects</topic><topic>Carteolol - pharmacology</topic><topic>Cell Line</topic><topic>Compliance</topic><topic>Cornea</topic><topic>Cytotoxicity</topic><topic>Drug Combinations</topic><topic>Drug dosages</topic><topic>Epithelial cells</topic><topic>Epithelium, Corneal - drug effects</topic><topic>Glaucoma</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Intraocular Pressure - drug effects</topic><topic>Latanoprost - administration & dosage</topic><topic>Latanoprost - adverse effects</topic><topic>Latanoprost - pharmacology</topic><topic>Macaca fascicularis</topic><topic>Male</topic><topic>multidisciplinary</topic><topic>Pharmaceuticals</topic><topic>Prostaglandins F - administration & dosage</topic><topic>Prostaglandins F - adverse effects</topic><topic>Prostaglandins F - pharmacology</topic><topic>R&D</topic><topic>Research & development</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Timolol</topic><topic>Timolol - administration & dosage</topic><topic>Timolol - adverse effects</topic><topic>Timolol - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fuwa, Masahiro</creatorcontrib><creatorcontrib>Shimazaki, Atsushi</creatorcontrib><creatorcontrib>Mieda, Masafumi</creatorcontrib><creatorcontrib>Yamashita, Naoko</creatorcontrib><creatorcontrib>Akaishi, Takahiro</creatorcontrib><creatorcontrib>Taniguchi, Takazumi</creatorcontrib><creatorcontrib>Kato, Masatomo</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fuwa, Masahiro</au><au>Shimazaki, Atsushi</au><au>Mieda, Masafumi</au><au>Yamashita, Naoko</au><au>Akaishi, Takahiro</au><au>Taniguchi, Takazumi</au><au>Kato, Masatomo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2019-05-16</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>7491</spage><pages>7491-</pages><artnum>7491</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>In this study, we made a comparative efficacy and safety assessment of two different fixed combinations of drugs, viz., tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more effective in lowering IOP for a longer duration compared to LAT/CAR. We found that the difference in the intensity of IOP-lowering effect was because of the differences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafluprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic effects compared to LAT/CAR on the human corneal epithelial cells. Our findings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering effect in monkeys and toxicity on ocular surface.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31097790</pmid><doi>10.1038/s41598-019-44028-2</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2019-05, Vol.9 (1), p.7491, Article 7491 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6522485 |
| source | Nature Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry; Springer Nature OA Free Journals |
| subjects | 631/154/436/2388 692/308/2778 692/699/3161/3169/3170 Animals Antihypertensive Agents - administration & dosage Antihypertensive Agents - adverse effects Antihypertensive Agents - pharmacology Carteolol - administration & dosage Carteolol - adverse effects Carteolol - pharmacology Cell Line Compliance Cornea Cytotoxicity Drug Combinations Drug dosages Epithelial cells Epithelium, Corneal - drug effects Glaucoma Humanities and Social Sciences Humans Intraocular Pressure - drug effects Latanoprost - administration & dosage Latanoprost - adverse effects Latanoprost - pharmacology Macaca fascicularis Male multidisciplinary Pharmaceuticals Prostaglandins F - administration & dosage Prostaglandins F - adverse effects Prostaglandins F - pharmacology R&D Research & development Science Science (multidisciplinary) Timolol Timolol - administration & dosage Timolol - adverse effects Timolol - pharmacology |
| title | Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T05%3A43%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20the%20fixed%20combinations%20of%20tafluprost/timolol%20and%20latanoprost/carteolol&rft.jtitle=Scientific%20reports&rft.au=Fuwa,%20Masahiro&rft.date=2019-05-16&rft.volume=9&rft.issue=1&rft.spage=7491&rft.pages=7491-&rft.artnum=7491&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-019-44028-2&rft_dat=%3Cproquest_pubme%3E2226432396%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2226432396&rft_id=info:pmid/31097790&rfr_iscdi=true |